A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT01519804. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV squamous non-small cell lung cancer (NSCLC). Patients will be randomized to receive either onartuzumab (MetMAb) 15 mg/kg iv or placebo on Day 1 of each 21-day cycle in combination with 4 cycles of paclitaxel 200 mg/m2 iv and platinum (carboplatin/cisplatin) iv on Day 1 of each 21-day cycle. Patients who have not progressed after 4 cycles will continue with either onartuzumab (MetMAb) or placebo as maintenance therapy until disease progression or unacceptable toxicity occurs.
Study identification
- NCT ID
- NCT01519804
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2012 (Type not available)
- Primary completion
- Jan 2014 (Actual)
- Completion
- Sep 2015 (Actual)
- Last update posted
- Sep 2, 2016
2012 – 2015
United States locations
- U.S. sites
- 34
- U.S. states
- 18
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | 35805 | — |
| Not listed | Scottsdale | Arizona | 85259 | — |
| Not listed | Bakersfield | California | 93309 | — |
| Not listed | Fullerton | California | 92835 | — |
| Not listed | Los Angeles | California | 90024 | — |
| Not listed | Los Angeles | California | 90095-1772 | — |
| Not listed | Northridge | California | 91328 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | San Luis Obispo | California | 93454 | — |
| Not listed | Santa Barbara | California | 93105 | — |
| Not listed | Stanford | California | 94305 | — |
| Not listed | Grand Junction | Colorado | 81502-1628 | — |
| Not listed | Boynton Beach | Florida | 33435 | — |
| Not listed | Orlando | Florida | 32804 | — |
| Not listed | Weston | Florida | 33331 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Harvey | Illinois | 60426 | — |
| Not listed | Fort Wayne | Indiana | 46815 | — |
| Not listed | Fort Wayne | Indiana | 46845 | — |
| Not listed | Indianapolis | Indiana | 46260 | — |
| Not listed | Muncie | Indiana | 47303 | — |
| Not listed | Metairie | Louisiana | 70006 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Minneapolis | Minnesota | 55454 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Las Vegas | Nevada | 89148 | — |
| Not listed | Hickory | North Carolina | 28602 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Middletown | Ohio | 45042 | — |
| Not listed | Bend | Oregon | 97701 | — |
| Not listed | Pittsburgh | Pennsylvania | 15232 | — |
| Not listed | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01519804, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2016 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01519804 live on ClinicalTrials.gov.